A platform that can diagnose several diseases with a high degree of precision using metabolic markers found in patients’ blood has been developed by scientists at the University of Campinas (UNICAMP) in Brazil.
The method combines mass spectrometry, which can identify tens of thousands of molecules present in blood serum, with an artificial intelligence algorithm capable of finding patterns associated with diseases of viral, bacterial, fungal and even genetic origin.
“We used infection by Zika virus as a model to develop the platform and showed that in this case, diagnostic accuracy exceeded 95%. One of the main advantages is that the method doesn’t lose sensitivity even if the virus mutates,” said Melo’s supervisor Rodrigo Ramos Catharino, principal investigator for the project. Catharino is a professor at UNICAMP’s School of Pharmaceutical Sciences (FCF) and head of its Innovare Biomarker Laboratory.
Another strength of the platform, he added, is the capacity to identify positive cases of Zika even in blood serum analyzed 30 days after the start of infection, when the acute phase of the disease is over.
“None of the currently available diagnostic kits has the sensitivity to detect infection by Zika after the end of the acute phase. The method we developed could be useful to analyze transfusion blood bags, for example,” Catharino said.
Development and validation of the platform involved analysis of blood samples from 203 patients treated at UNICAMP’s general and teaching hospital. Of these, 82 were diagnosed with Zika by the method currently considered the gold standard in this field: real-time polymerase chain reaction (RT-PCR), which detects viral RNA in body fluids during the acute phase of the infection.
The other 121 patients were the control group. Approximately half had the same symptoms as the group that tested positive for Zika, such as fever, joint pain, conjunctivitis and rash, but had negative RT-PCR results for Zika. The rest had no symptoms and also tested negative or were diagnosed with dengue.
All collected samples were analyzed in a mass spectrometer, a device that acts as a kind of molecular weighing scale, sorting molecules according to their mass.
“We identified some 10,000 different molecules in the patients’ serum, including lipids, peptides, and fragments of DNA and RNA. Among these metabolites, there were particles produced both by Zika and by the patient’s immune system in response to the infection,” Catharino said.
All the data obtained in the spectrometry analysis of both the group that tested positive for Zika and the control group were then fed into a computer program running a random-forest machine learning algorithm. This type of artificial intelligence tool is capable of analyzing a large amount of data by specific statistical methods in search of patterns that can be used as a basis for classification, prediction, decision making, modeling and so on.
“The algorithm separates samples randomly, determines which one will be the training group and the blind group, and then carries out testing and validation. At the end, it tells us whether with that number of samples it was possible to obtain a set of metabolic markers capable of identifying patients infected by Zika,” Catharino explained.
Each new set of patient data fed into the program enhances its learning capacity and makes it more sensitive, he went on. In the case of Zika, a panel of 42 biomarkers was established as a specific key to identifying the virus. Twelve of these were found by the algorithm to be highly prevalent in the blood of patients who tested positive for the disease.
“In this platform, it isn’t important to know a lot individually about each of the molecules that serve as markers of the infection. It’s the set that matters and that will tell us with a high level of accuracy whether we’re looking at Zika. Moreover, even if the virus mutates, the program adapts and changes too. It’s not a static methodology,” Catharino said.
The UNICAMP group is currently performing tests to evaluate the platform’s capacity to diagnose systemic diseases caused by fungi. They also plan to test how well it detects bacterial and genetic diseases. Anderson de Rezende Rocha, a professor at the same university’s Institute of Computing (IC-UNICAMP), is collaborating on the research.
In the cloud
In theory, any laboratory equipped with a mass spectrometer could use the new diagnostic platform developed at UNICAMP. Mass spectrometers are routinely used in procedures such as measuring vitamin D and screening blood spots from newborns to detect metabolic diseases via the heel prick test.
“Our proposal is to make the platform available in the cloud, so that it can be downloaded to any mass spectrometer anywhere in the world. Data analysis can be performed online. Whether it would be free or paid is yet to be defined,” Catharino said.
The Latest on: Artificial intelligence diagnostics
via Google News
The Latest on: Artificial intelligence diagnostics
- Artificial Intelligence (AI) in Drug Discovery Market Worth $1,434 Million by 2024 - Exclusive Report by MarketsandMarkets™on November 19, 2019 at 7:06 am
Artificial Intelligence (AI) in Drug Discovery Market Worth $1,434 Million by 2024 - Exclusive ... precision medicine, medical imaging and diagnostics, and patient data and risk analysis, among others ...
- Artificial Intelligence can transform field operations. Here’s howon November 19, 2019 at 12:23 am
When a piece of equipment breaks down, it can take days or weeks to get it fixed, whether because of diagnostic issues ... This level of automation is the promise of artificial intelligence (AI) in ...
- Human–machine partnership with artificial intelligence for chest radiograph diagnosison November 18, 2019 at 2:18 am
Diagnostic accuracy of the swarm-based technology was compared against the human ... The full process of deliberation for each case, as moderated by the real-time swarm artificial intelligence ...
- Armenian EyeCare Project Surpasses Milestone of 10,000 Patients Screened Using Artificial Intelligence Eye Screening Technologyon November 14, 2019 at 5:17 am
“We applaud the vision exemplified by Dr. Ohanesian and the AECP organization in preserving vision for diabetes patients in Armenia, and we hope that medical breakthroughs such as AI medical ...
- Artificial Intelligence (AI) in Medical Diagnostics: 2019 Patent Landscape Reporton November 12, 2019 at 4:35 am
Dublin, Nov. 12, 2019 (GLOBE NEWSWIRE) -- The "Artificial Intelligence in Medical Diagnostics: Patent Landscape" report has been added to ResearchAndMarkets.com's offering. With the development of ...
- Huge Untapped Potential of Artificial Intelligence in Healthcareon November 12, 2019 at 2:17 am
and artificial intelligence (AI) to disrupt industries. AI is already seeing a wide application in industries such as finance, education, robotics, transportation, security, and to an extent in ...
- Aimia turns to artificial intelligence to lift its data gameon November 10, 2019 at 12:44 pm
Which is why the leader in loyalty marketing, services, technology, and data platforms recently turned to artificial intelligence (AI), to better ... we are really excited about smart journey ...
- How Entrepreneurs Can Take on the Future of Aging Using Artificial Intelligenceon November 7, 2019 at 1:00 pm
This is a huge opportunity for entrepreneurs to study sleep challenges as a person ages and then brainstorm and create effective palatable solutions. Work on and invest in diagnostic technologies. AI ...
- Study shows artificial intelligence can detect language problems tied to liver failureon November 7, 2019 at 9:58 am
Overall, the researchers found that NLP detected distinct, yet subtle, pre-transplant and post-transplant differences in sentence length, word length and other language characteristics, suggesting ...
via Bing News